Key clinical point: Once-weekly tirzepatide vs insulin degludec effectuates superior glycemic control, as measured by continuous glucose monitoring, in patients with inadequately controlled type 2 diabetes (T2D) on metformin with or without a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
Major finding: At 52 weeks, patients receiving 5 mg tirzepatide (estimated treatment difference [ETD] 12%; P = .031), 10 mg (ETD 24%; P < .0001), and 15 mg (ETD 25%; P < .0001) vs insulin degludec spent significantly more time in the tight target range (blood glucose concentration 71-140 mg/dL).
Study details: This substudy of the SURPASS-3 trial included 243 insulin-naive patients with type T2D inadequately controlled on metformin with or without an SGLT2 inhibitor who were randomly assigned to receive once-weekly tirzepatide (5, 10, or 15 mg; n = 188) or insulin degludec (n = 55).
Disclosures: The study was funded by Eli Lilly and Company. Two authors reported being consultants or receiving advisory board member or speaker honoraria from various sources, including Eli Lilly. The other authors are employees and shareholders of Eli Lilly.
Source: Battelino T et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):407-417 (Apr 22). Doi: 10.1016/S2213-8587(22)00077-8